ALMS ALUMIS INC. Insider Trading

Director Akkaraju Srinivas buys 588,235 shares of ALMS at $17.00 ($10.0M); stock now at $22.11, +92.4% in 30 days. Cluster pattern: 3 other insiders also bought within 14 days.

Director Akkaraju Srinivas purchased 588,235 shares at $17.00 for $9,999,995.00 on 2026-01-09, increasing his holdings by 46.5% to 1,853,488 shares. The stock has appreciated sharply to $22.11 (currently at 52-week high), with a +92.4% gain in 30 days and +355.9% gain over 90 days. This buy occurs as part of a cluster pattern—3 other insiders purchased within the preceding 14 days—signaling coordinated accumulation activity. However, context is critical: the company generated only $2.1M in revenue and reported a net loss of $-110.8M in its most recent quarter, with full-year results also unprofitable. At this ticker, Srinivas's 5 prior buys show mixed near-term outcomes (ranging from -16.5% to +15.6% at 30 days), with no measurable 90-day results yet, and his cross-ticker track record (20 prior buys) shows a 100% 90-day win rate at +8.6% average—but that cross-ticker record does not necessarily predict performance in a company with severe profitability challenges.

Foresite Capital Management VI LLC (10% Owner) bought 411,764 shares at $17.00 in 2 transactions totaling $7.0M on 2026-01-08

Foresite Capital Management VI LLC, a 10% holder, deployed $7.0M across 2 separate purchases totaling 411,764 shares (411.8K shares) at $17.00 on 2026-01-08, increasing holdings by 16.5% from 2.50M to 2.91M shares. The stock has rallied 83.6% over the past 30 days and is at its 52-week high of $21.09, suggesting the insider bought after significant momentum had already accumulated. At the same-ticker level, Foresite executed 5 consecutive buys between 2025-11-17 and 2025-11-21, all of which showed positive 30-day returns (+53.0% to +89.3%), yet none have reached measurable 90-day outcomes to validate timing accuracy. The cluster pattern—3 other insiders also buying within the past 14 days—may indicate coordinated conviction, though the fundamental picture remains concerning: the company reported $2.1M in quarterly revenue and a $-110.8M net loss, with full-year profitability negative. The sustained accumulation at elevated valuations against deteriorating earnings raises questions about whether the buying reflects confidence in near-term catalysts or momentum-driven positioning.

10% owner Foresite Labs buys 411,764 shares for $7.0M at $17.00 on 2026-01-08; stock +83.6% in 30 days post-transaction amid unprofitable operations.

Foresite Labs executed 2 separate purchases totaling 411,764 shares for $6,999,988.00 at $17.00 per share on 2026-01-08, increasing its holdings by 16.5% to 2,908,332 shares. This substantial capital commitment ($7.0M) comes as the stock has rallied 83.6% in the 30 days following the transaction and trades at $21.09, matching its 52-week high. The purchase occurs within a tight cluster of 4 insider buys across 14 days. However, this bullish activity is offset by deteriorating fundamentals: Alumis reported quarterly revenue of $2,066,000 and net loss of $-110,752,000, underscoring the company's unprofitable status. The 10% owner's track record across all holdings shows a 90-day win rate of 0.00%, and his prior ALMS transactions (5 buys in mid-November) remain too recent to measure 90-day outcomes, leaving open whether near-term price strength reflects sustainable business improvement or momentum-driven repricing.

Director James B. Tananbaum buys 411,764 shares at $17.00 for $6,999,988.00; stock now at $21.09 (+83.6% in 30 days). Company unprofitable.

Director James B. Tananbaum executed 2 separate purchases totaling 411,764 shares for $6,999,988.00 at $17.00 on 2026-01-08, increasing his holdings by 16.5% to 2,908,332 shares post-transaction. The stock has surged 83.6% over the past 30 days and now trades at $21.09, approaching its 52-week high of $21.09. However, the company remains materially unprofitable with net income of $-110,752,000.00 over its most recent full fiscal year and quarterly revenue of only $2,066,000.00—raising questions about the fundamental basis for such significant insider accumulation at an already-elevated valuation. A cluster pattern of 3 other insiders buying within the past 14 days amplifies the signal, though Tananbaum's own cross-ticker track record shows a 90-day win rate of 33.33% with an average 90-day return of -11.7%, suggesting his timing has historically not been reliable beyond the near term.

Director AKKARAJU SRINIVAS bought 186,377 shares across 3 transactions totaling $1,833,760.23, raising stake 17.3%

AKKARAJU SRINIVAS executed three separate purchases totaling 186,377 shares for $1,833,760.23 on 2025-12-05, with a blended average price of $9.84 per share. The current price of $11.43 sits at the 52-week high, and the stock has surged +142.2% in the last 30 days and +165.8% over 90 days; his purchases occurred during this explosive rally. His cross-ticker track record shows an average 30-day return of -25.0% on 20 prior buys, and his five recent same-ticker purchases at ALMS (2025-11-28 through 2025-12-04) have not yet reached measurable return windows. The company remains deeply unprofitable with $-110,752,000.00 net income (latest fiscal year) on only $2,066,000.00 quarterly revenue. This accumulation substantially increases his holdings from 1,078,876 to 1,265,253 shares, but the combination of poor historical buy-timing and severe fundamental distress warrants scrutiny of the transaction's underlying rationale.

Director Srinivas buys 262,027 shares in 3 tranches (Dec 2-4) at $7.79 avg; stock now $8.30, co unprofitable.

AKKARAJU SRINIVAS (Director) executed 3 separate purchases totaling 262,027 shares for $2,039,900.86 between 2025-12-02 and 2025-12-04, at prices ranging from $7.55 to $8.18 (blended average $7.79). His shareholding increased 32.1% from 816,849 to 1,078,876 shares. The purchases occur during a period of sharp upward price momentum: the stock is 30-day +82.4% and 90-day +84.0%, though it remains 17.6% below the 52-week high of $10.07. The fundamental backdrop is concerning: the company reported quarterly revenue of $2,066,000.00 and a net loss of $-110,752,000.00, with unprofitability over its most recent full fiscal year. A cluster pattern is present—3 other insiders also bought within the past 14 days. Srinivas's cross-ticker track record shows 20 prior buys with a 90-day win rate of 33.33% and average 90-day return of +10.9%, but his same-ticker history at ALMS consists of 5 recent buys (Nov 19 through Dec 1) with outcomes not yet measurable.

Director AKKARAJU SRINIVAS buys 173,589 shares in 3 tranches (173.6K) for $1,310,676.96 across 6 days at ALMS

AKKARAJU SRINIVAS purchased 173,589 shares in three separate transactions between 2025-11-26 and 2025-12-01, increasing his holdings by 27.0% to 816,849 shares total. The purchases occurred at prices of $7.64, $7.64, and $7.46, with a blended average of $7.55, during a period when the stock has appreciated 54.7% over 30 days and 56.4% over 90 days despite trading 27.0% below its 52-week high of $10.07. This buying activity coincides with a cluster pattern where 3 other insiders also purchased within the past 14 days. However, Alumis Inc. reported a net loss of $110,752,000.00 in its most recent full fiscal year and continues to operate unprofitably, with quarterly revenue of $2,066,000.00. The director's cross-ticker track record shows an average 90-day return of -6.3% on 19 prior buys with a 25.00% win rate, raising questions about the predictive value of this accumulation activity.

Director Tananbaum buys 72,212 shares of ALMS at $7.38; 4 buys in 5 days amid -$110.8M annual loss

James B. Tananbaum (Director) purchased 72,212 shares at $7.38 on 2025-11-21, expanding his holdings from 2,542,003 to 2,614,215 shares (+2.8%). This transaction is part of a concentrated buying cluster: Tananbaum executed four separate purchases at ALMS within five calendar days (2025-11-17 through 2025-11-21), suggesting deliberate accumulation activity. The timing coincides with strong recent price momentum (30-day change: +62.5%, 90-day change: +49.0%), placing the current price $7.33 at -27.2% from the 52-week high of $10.07. However, the company's fundamentals present a significant concern: latest-quarter revenue was only $2,066,000.00 while the company posted a net loss of $-110,752,000.00 and was unprofitable over its most recent full fiscal year. Tananbaum's prior buy at this same ticker on 2025-05-06 declined -5.8% over 90 days, and his cross-ticker track record shows a 33.33% win rate on buys with an average 90-day return of -11.7%, suggesting a pattern of poorly-timed purchases. The rapid-fire accumulation in an unprofitable microcap with deteriorating fundamentals warrants investor scrutiny.

10% owner Foresite Capital buys 72,212 shares of ALMS at $7.38 amid cluster activity; company unprofitable with -$110.8M net loss.

Foresite Capital Management VI LLC, holding 2.61M shares post-transaction, purchased 72,212 shares at $7.38 on 2025-11-21 as part of a three-insider buying cluster within the past 14 days. The company's fundamentals are concerning: quarterly revenue of $2.1M paired with a net loss of -$110.8M and full-year unprofitability signal severe operational stress. Foresite's cross-ticker track record shows weak performance (6 prior buys with 0% 90-day win rate and avg 90d return of -8.1%), though at ALMS specifically only one prior buy is measurable (2025-05-06 returned -5.8% at 90 days). The stock is currently down 27.2% from its 52-week high despite 30-day momentum of +62.5%, suggesting recent volatility without resolution of underlying profitability challenges. The cluster pattern and recent rapid succession of purchases (three buys within two days) warrant scrutiny alongside the fundamental deterioration.

Foresite Labs (10% owner) bought 72,212 shares of ALMS at $7.38; 4 buys in 5 days amid -$110.8M net loss.

Foresite Labs purchased 72,212 shares on 2025-11-21 at $7.38, expanding its stake to 2,614,215 shares (+2.8% from pre-transaction holdings). This transaction is one of five purchases at ALMS within five days (2025-11-17 through 2025-11-21), alongside a cluster of 3 other insiders buying within the past 14 days. The timing occurs within a volatile price environment: ALMS is currently $7.33 (-27.2% from its 52-week high of $10.07) but +62.5% over the last 30 days. However, the company reported a net loss of -$110,752,000.00 in its most recent full fiscal year and a latest quarterly revenue of only $2,066,000.00, signaling severe unprofitability. Foresite Labs' cross-ticker track record shows 0% accuracy at the 90-day mark across 8 prior open-market buys (average 90d return -19.2%), and its one measurable prior trade at ALMS (2025-05-06) generated a -5.8% 90-day return. The rapid succession of insider purchases against deteriorating fundamentals and poor historical timing outcomes presents a complex signal: coordinated accumulation may reflect conviction in near-term recovery, but the insider's track record and the company's financial distress warrant caution.